Vivimed Labs Ltd

Key disclosures and actions

• Approved submission of audited standalone and consolidated results for quarter and year ended 31 March 2026.
• Auditors' report issued with qualified opinion due to non-recognition of interest on SBI borrowings assigned to ARC.
• Board powers suspended under CIRP; Interim Resolution Professional appointed to manage the company.
• NCLT admitted CIRP; CoC held first meeting on 13 May 2026.
• SBI borrowings assigned to ARC under SARFAESI; liability remains payable to ARC.
• One Time Settlement with Bank of Bahrain and Kuwait for Rs 40.05 million; 10 million paid; impact pending.
• IFC ECB loan of USD 2.36 million; proposed OTS for USD 0.80 million; approval pending.
• Inventory written down by Rs 233.08 million; primarily WIP due to working capital constraints.
• Deferred revenue expenditure of Rs 209.80 million identified; entry recorded; recoverability under assessment.
• IND-AS 108: Group primarily Pharma; segment reporting not applicable.
• Auditors' Emphasis of Matter: CBI investigation and CIRP; no adjustments.
• Vivimed Pharma Mauritius sold stake in Uquifa Sciences (Mascarene) Limited; no impairment.
• Consolidated results include unaudited subsidiaries; basis noted in report.

CoC meeting details

• 8th CoC meeting under CIRP scheduled for September 29, 2026 via audio-visual means.
• Pre-Facto intimation of meeting under CIRP with NCLT order dated 15 April 2026.
• Narayana Swamy acting as Interim Resolution Professional, functioning as RP under IBC.
• IBBI registration: IBBI/IPA-002/IP-N01078/2020-2021/13427; AFA valid to 30 June 2027.
• Stock exchanges: NSE symbol VIVIMEDLAB; BSE code 532660.

CoC extends AGM timeline

• CoC approved filing with ROC Bangalore to extend AGM for FY 2025-26 by three months.
• Decision was taken by Resolution by Circulation on 25 September 2026.

Vivimed Labs Limited trading window closed from 01.10.2026 until 48 hours after the declaration of the financial results for the quarter and half year ended September 30, 2026

Vivimed Labs Ltd - Trading Window Closure from 01.10.2026 till 48 hours after the declaration of the Financial Results for the quarter & half year ended September 30, 2026, which becomes generally available information.

CoC meeting details

• 7th CoC meeting for Vivimed Labs Limited under CIRP scheduled on 10 September 2026.
• Meeting will be held via Audio-Visual Means as per IBC regulations.
• IRP: T Narayana Swamy, functioning as RP under Section 16(5) of IBC.
• NCLT order dated 15 April 2026 initiated CIRP.

Upcoming CoC meeting

• Sixth CoC meeting for Vivimed Labs under CIRP on 18 Aug 2026 via audio-visual means.
• Pre-Facto intimation under CIRP Regulations for the upcoming meeting.
• Previous meetings: Third on 18-06-2026; Fourth on 04-07-2026; Fifth on 20-07-2026.
• Notice date: 17 Aug 2026.
• Interim Resolution Professional: Narayana Swamy.